Compass Ion Advisors’s AstraZeneca AZN Stock Holding History

Compass Ion Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Hold	1,110	–	–	0.02%	284
2026 Q1	$219K	Buy	+1,110	New	+$214K	0.02%	262
2024 Q4	–	Sell	-1,365	Closed	-$213K	–	260
2024 Q3	$213K	Sell	1,365 -317	-19%	-$51.2K	0.03%	248
2024 Q2	$228K	Hold	1,682	–	–	0.03%	213
2024 Q1	$228K	Sell	1,682 -118	-7%	-$15.6K	0.03%	213
2023 Q4	$242K	Sell	1,800 -430	-19%	-$55.9K	0.04%	206
2023 Q3	$302K	Buy	+2,230	New	+$305K	0.05%	182

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Compass Ion Advisors's AZN Position: Q2 2026 in Review

Compass Ion Advisors held its AstraZeneca (AZN) position steady in Q2 2026 at 1,110 shares worth $210K. The position accounts for 0.02% of the portfolio, ranked #284.

Compass Ion Advisors first reported a position in AZN in Q3 2023 and has held it in 7 quarters since. The position peaked at $302K in Q3 2023. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Compass Ion Advisors held 1,110 shares of AstraZeneca worth $210K as of Q2 2026.
Compass Ion Advisors left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.02% of Compass Ion Advisors's portfolio in Q2 2026, its #284 holding.
Compass Ion Advisors first reported a position in AstraZeneca in Q3 2023 and has held it in 7 quarters since.
Compass Ion Advisors's AstraZeneca position peaked at $302K in Q3 2023.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Compass Ion Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.